Ameliorative effect of flavonoid-rich extracts from Gongronema latifolium against diabetic cardiomyopathy via serpin A3 and socs3-a in streptozocin treated rats

Biomarkers. 2022 Mar;27(2):169-177. doi: 10.1080/1354750X.2021.2023220. Epub 2022 Jan 25.

Abstract

Introduction: The present study access the effect of the flavonoid-rich extract from Gongronema latifolium against cardiomyopathy streptozotocin-induced diabetic rats.

Materials and methods: The flavonoid-rich extract from G. latifolium leaf (FREGL) was prepared using a standard method. Diabetes was induced by a single intraperitoneal (i.p.) injection of streptozotocin. The experimental animals were divided into five groups as non-diabetic rats, diabetic control, diabetic rats administered low and high doses of FREGL (13 and 26 mg/kg), and metformin-glibenclamide orally for 21 days. Hence, the experimental animals were sacrificed; blood and heart were harvested to determine diverse biochemical parameters, including the gene expressions of serpin A3 and socs3-a as well as histological examination.

Results: The results demonstrated that FREGL significantly (p < 0.05) reduced fasting blood glucose, total cholesterol, low density lipoprotein (LDL), triglyceride (TG), lipid peroxidation levels, as well as the activities of lactate dehydrogenase and creatine kinase-MB, including the relative gene expressions of serpin A3 and Socs3-A in diabetic rats. Also, diabetic rats that received different doses of FREGL showed a substantial rise in insulin and high density lipoprotein (HDL) levels, antioxidant enzyme activities, as well as, normal histoarchitecture of the heart tissues.

Conclusion: Therefore, FREGL may be beneficial in alleviating diabetic cardiomyopathy.

Keywords: Isolate; antioxidant enzymes; flavonoid; gene expression; histology; lipid profiles.

MeSH terms

  • Animals
  • Apocynaceae* / metabolism
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetic Cardiomyopathies* / drug therapy
  • Flavonoids / pharmacology
  • Flavonoids / therapeutic use
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Plant Extracts / pharmacology
  • Rats
  • Rats, Wistar
  • Serpins*
  • Streptozocin / adverse effects
  • Suppressor of Cytokine Signaling 3 Protein

Substances

  • Blood Glucose
  • Flavonoids
  • Hypoglycemic Agents
  • Plant Extracts
  • SOCS3 protein, human
  • Serpins
  • Socs3 protein, rat
  • Suppressor of Cytokine Signaling 3 Protein
  • Streptozocin